AQR Capital Management
KROS icon

AQR Capital Management’s Keros Therapeutics KROS Stock Holding History

AQR Capital Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.49M Buy
406,563
+226,020
+125% +$3.49M ﹤0.01% 1820
2025
Q4 		$3.68M Sell
180,543
-23,808
-12% -$418K ﹤0.01% 1764
2025
Q3 		$3.23M Buy
204,351
+133,701
+189% +$1.98M ﹤0.01% 1698
2025
Q2 		$943K Buy
70,650
+48,514
+219% +$655K ﹤0.01% 2239
2025
Q1 		$226K Buy
+22,136
New +$257K ﹤0.01% 2824
2023
Q3 		– Sell
-11,441
Closed -$460K – 2344
2023
Q2 		$460K Buy
11,441
+3,850
+51% +$169K ﹤0.01% 1813
2023
Q1 		$324K Buy
+7,591
New +$383K ﹤0.01% 1924

Other funds holding KROS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

AQR Capital Management's KROS Position: Q1 2026 in Review

AQR Capital Management increased its Keros Therapeutics (KROS) stake by 125% in Q1 2026, buying an estimated $3.49M and bringing the position to 406,563 shares worth $4.49M. The position accounts for ﹤0.01% of the portfolio, ranked #1820.

AQR Capital Management first reported a position in KROS in Q1 2023 and has held it in 7 quarters since. 151 funds tracked by Wall St. Rank hold KROS as of Q1 2026.

  • AQR Capital Management held 406,563 shares of Keros Therapeutics worth $4.49M as of Q1 2026.
  • AQR Capital Management bought 226,020 Keros Therapeutics shares in Q1 2026, an estimated $3.49M.
  • Keros Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1820 holding.
  • AQR Capital Management first reported a position in Keros Therapeutics in Q1 2023 and has held it in 7 quarters since.
  • 151 funds tracked by Wall St. Rank held Keros Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.